Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals Form 144 filing summary — This notice reports a proposed sale of 16,000 shares of the issuer's common stock through Stifel Nicolaus & Company, Inc. with an aggregate market value of $703,642.00. The sale is scheduled approximately for 08/18/2025 on Nasdaq. The filing lists prior acquisitions underlying the shares: an option exercise on 01/03/2022 totaling 28,869 shares, restricted stock units granted on 01/15/2017 for 7,537 shares, and restricted stock units on 01/15/2016 for 6,373 shares. The table for sales during the past three months shows Nothing to Report. Several identifying fields (filer CIK/CCC and the named person for whose account the sale is proposed) are not provided in the content.
Ionis Pharmaceuticals director Lynne B. Parshall reported selling 5,000 shares of common stock on August 6, 2025, in open-market transactions at weighted average prices of $41.8685 and $42.6275 per share under a Rule 10b5-1 trading plan adopted May 6, 2025. After these sales, she holds 86,344 shares directly.
Filing type: Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS).
Proposed sale: 10,000 shares of Common Stock through Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) on 08/06/2025, with an aggregate market value of $419,292.00. The filing lists 159,391,229 shares outstanding.
Acquisition details: 42,223 shares were acquired as Restricted Stock Units on 01/15/2017; payment: Cash. The filing shows "Nothing to Report" for securities sold in the past 3 months. The filer identity/CIK and submission contact fields are not provided in the form content.
Ionis Pharmaceuticals (IONS) filed a Form 4 stating that EVP & Chief Clinical Development Officer Eugene Schneider sold 9,549 common shares on 08/04/2025 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted 05/02/2025. The weighted-average sale price was $42.8004, with individual trades executed between $42.315 and $43.45. Gross proceeds are roughly $0.41 million.
Following the disposition, Schneider directly owns 51,507 shares; the sale reduced his direct stake by approximately 15.6 % (from 61,056 shares). No derivative securities were involved. The filing is a routine Section 16 disclosure and does not affect the company’s operations or guidance.